Team Members
We have highly trained staff with International and National Experience
Umar Hayat, Ph.D. is a founder of Trials 360 and has more than two decades of experience in pharmaceutical development, manufacturing and supply chain. He held senior level positions with, Union Therapeutics, Relypsa (acquired by Galenica for 1.52B US$), Anacor (acquired by Pfizer for 5.2B US$) and Transcept Pharmaceuticals (revers merger with Paratek). He played a pivotal role in the development and commercialization of Veltassa® (USA and EU), a treatment for hyperkalemia, Intermezzo® for MOTN insomnia, Kerydin® for onychomycosis, and Eucrisa® for atopic dermatitis.
Dr. Hayat is managing partner of Revive Pharm USA. He is also a co-founder of U&D Pharma, a company working on Replyte Gel, a treatment for anogenital warts.
Dr. Hayat received his Ph.D. in process engineering from INP-Toulouse, France and Post-Doctoral Fellowship from Ecole Polytechnique de Montreal, Canada. He received M.Sc. Chemistry degree from Punjab University, Institute of Chemistry. Pakistan.
Imran Naveed got his degree Doctor of pharmacy (PharmD) from Baha Uddin Zakarya University Multan. He also served Pfizer as a Professional Services Representative for more than one year. Moreover, he served as a retail pharmacist at Fazal Din Pharma Plus Lahore for one year. During his tenure he built his strong relationship with the key opinion health care professionals and Hospitals.
Imran Naveed is a head of pharmaceutical development at Trials 360⁰, CRO (Subsidiary of HP Consulting, USA). He has vast experience of pharmaceutical manufacturing, investigational products, transportation, and formulation.
He is CEO of B.S Enterprises having physical business in Lahore with annual turnover of 20 million in surgical and non-surgical imports and supply. He has good professional relations in secondary and tertiary healthcare sectors of Pakistan.
Dr Maytom is a partner in RAND bio-Partners Inc. a pharmaceutical R&D consultancy group. During more than 20 years in the pharmaceutical industry in clinical development and medical affairs, Dr. Maytom has worked both in the US and the EU. Dr. Maytom joined the pharmaceutical industry as Country Medical Advisor to Rhône Poulenc Rorer, UK. He subsequently worked as a Medical Director at Pfizer’s UK R&D facility, and following a successful NDA submission, he transitioned to Pfizer’s New York Headquarters to provide International and North American medical product support. After 10 years at Pfizer Dr Maytom became Acting CEO of a privately held start-up company in Oxford, UK. On his return to the US, he worked in various R&D and Medical Affairs roles in CNS: including Chief Medical Officer at two companies engaged in 505(b)(2) clinical programs.
As an independent consultant to the pharmaceutical industry Dr Maytom continues to demonstrate great versatility and a wide breadth of clinical experience, working in a wide range of medical indications including Neurology, Psychiatry, Dermatology, Endocrinology, Oncology, Ophthalmology, Urology, Sexual Medicine, Orthopedics and Cardiology as a clinical development advisor, and as a study consultant providing medical guidance, safety monitoring and direct study support.
Dr. Khushbukhat Khan is a dedicated professional serving as the Oncology Lead for pre-clinical and clinical trials at Trials360, a prestigious subsidiary of Hayat Pharmaceutical Consulting based in California, USA. With over three years of extensive experience in oncology research and development, Dr. Khan has established herself as a leading expert in the field. Drawing from her remarkable expertise, Dr. Khan has contributed to the advancement of biotechnology companies in the UK and USA through her two years of remote consultancy services.
Dr. Khan earned her Ph.D. from the National University of Sciences and Technology (NUST), one of Asia’s premier institutions. Her work focused on identifying oncogenic markers at the gene and protein levels in the Pakistani population. Her research explored their potential as prognostic and diagnostic indicators. She also investigated natural compounds-based therapeutic options for breast cancer and hepatic cell carcinoma, providing promising alternatives to chemotherapy. Her current research endeavor is to understand the mechanisms that lead to chemoresistance in cancers and exploring alternative treatment options.
Beyond her research achievements, Dr. Khan is a passionate advocate for cancer awareness. She has actively contributed to this cause by delivering impactful talks on Television programs and Pakistan radio, disseminating crucial information and empowering individuals to take proactive steps in their health journey.
Dr. Khan was awarded the HEC indigenous Ph.D. fellowship in 2019. To date, Dr. Khan has published over 40 influential papers in prestigious scientific journals, one book chapter, and has filed two patents.
Dr. Saad Bin Shabbir graduated as a veterinarian in 2018. Following his undergraduate studies, he pursued further education and completed his MPhil in Microbiology from UVAS Lahore. During his MPhil program, he conducted research on the antiviral potential of an iodine complex against the Foot and Mouth Disease Virus using the BHK-21 cell line, publishing his findings in a reputed international journal.
After completing his MPhil, Dr. Saad gained practical experience as a research associate on a project titled “Production of Recombinant FMDV Vaccine,” funded by the Punjab Agriculture Research Board. Over the span of two years, he contributed significantly to the development and production of a recombinant Foot and Mouth Disease Virus (FMDV) vaccine, which is crucial for the prevention and control of this highly contagious disease in livestock.
Currently, Dr. Saad holds the position of Veterinary Scientist at Trails 360˚, a subsidiary of Hayat Pharmaceutical Consulting based in California, USA. In this role, he is involved in various pre-clinical research activities, contributing to the advancement of pharmaceutical products and ensuring their compliance with regulatory standards.
Iqra Mutiullah is a dedicated translational researcher at Trials 360, where she plays a pivotal role in bridging the gap between laboratory discoveries and practical applications in healthcare. With a Master’s degree in industrial biotechnology from the esteemed National University of Sciences and Technology (NUST), Iqra brings a wealth of knowledge and expertise to her role.
During her academic pursuits, Iqra’s research focused on the therapeutic effects of indigenous probiotics and functional foods in improving neurobiological conditions and gut health. Her innovative work aimed to unravel the intricate connections between the gut and the brain, paving the way for new therapeutic interventions. She also worked as a Research Associate on a project focused on treating Alzheimer’s with probiotics, advocating for the benefits of probiotics for mental health and gut wellness.
In her role at Trials 360, a subsidiary of Hayat Pharmaceutical Consulting based in California, USA, Iqra is responsible for developing research protocols that translate scientific discoveries into clinically relevant outcomes, all while considering the regulatory and ethical aspects of clinical research. Her meticulous approach to data analysis allows her to identify patterns, trends, and potential therapeutic implications, ensuring that research projects are conducted with precision and efficiency.
Daniyal Irfan is an Associate Translational Researcher at Trials360, where he specializes in converting early stage scientific discoveries into robust clinical strategies. In this role, Daniyal collaborates closely with his team to refine preclinical data, define biomarkers, and establish meaningful study endpoints—ensuring seamless alignment between laboratory insights and patient focused trial designs.
He holds a bachelor’s degree in biotechnology from Forman Christian University (FCU), where he researched on developing atrazine resistant local cotton strains. This work not only advanced crop resilience at the genetic and molecular levels but also underscored the importance of preserving native species against biotic stressors. Later, working at Punjab University’s School of Biological Sciences, Daniyal honed his expertise in molecular biotechnology and in silico protein engineering—applying these techniques to industrial applications, diagnostic development, and the study of dengue virus biology.
Prior to joining Trials360, Daniyal applied his analytical acumen to healthcare management software solutions, driving data driven improvements in system performance and user outcomes. Today, he leverages his skill and diverse experience to bridge the bench to bedside gap—transforming complex research into practical, patient centered clinical interventions.
Taha Asif is a Business graduate from Beaconhouse National University, with a specialization in Marketing. With a passion for strategic growth, client engagement, and innovation, Taha is driven to make an impact in the clinical research industry. As part of Trials 360, Taha aims to contribute meaningfully to advancing healthcare solutions through business development and collaborative partnerships.
Muhammad Salman Khalid is a seasoned professional with a Master’s degree in Business Administration and over two decades of diverse experience across multiple industries. His career began in the travel sector, where he worked with both IATA and non-IATA firms, establishing a strong foundation in customer service and operations. He then transitioned to Gulf Air, gaining valuable insights into the aviation industry.
His journey led him into the banking world, where he held various roles in operations, learning and development, and liability management, eventually rising to the position of Assistant Vice President. This experience provided him with a comprehensive understanding of financial services and strategic management.
Following a successful banking career, Muhammad Salman ventured into the IT industry, taking on the role of Head of HR and Finance Operations. This opportunity allowed him to expand his expertise in human resources and financial management within a technology-driven environment.
Currently, Muhammad Salman is the Head of HR at Trials360, where he plays a key role in recruitment and HR operations. With his extensive experience, he is dedicated to driving organizational success and fostering a positive workplace culture
Ehsan ul Haq work with Trial 360⁰ as office manager. He maintains office services by organizing procedures and operations, preparing payroll, controlling office records, and arranging necessary repairs. He received M.Sc. Applied Psychology degree from The Islamia University of Bahawalpur.
Muhammad Abu Bakar is a versatile IT Support Specialist and creative graphic designer at Trials360 Pvt. LTD, where he brings a unique blend of technical expertise and artistic flair to the team. With a Bachelor’s degree in Information Technology from the University of Sahiwal, he has built a career that spans across IT support, web development, and graphic design.
In his role as an IT Support Specialist, Muhammad excels in troubleshooting complex hardware, software, and network issues, ensuring seamless system operations and optimal performance. His strong problem-solving abilities, combined with his dedication to delivering high-quality technical support, allow him to maintain a reliable and efficient IT infrastructure.
As a graphic designer, Muhammad’s creative skills shine through in his ability to craft visually compelling designs that elevate brand identity and capture audience attention. Whether developing captivating websites or designing promotional materials, his keen eye for detail and design helps transform ideas into impactful visuals.
This unique combination of technical prowess and design creativity makes Muhammad a valuable asset to any project, allowing him to seamlessly bridge the gap between functionality and aesthetics, contributing to both the operational and creative success of the company.
Arslan Ali is a committed Research Associate at Trials360, where he plays a crucial role in managing the intersection of scientific innovation and clinical application. With a Master’s degree in Industrial Biotechnology from the National University of Sciences and Technology (NUST), Arslan Ali brings a strong foundation in molecular biology and biotechnology to his work.
His academic background is highlighted by extensive research in the molecular characterization of blood circulating protein biomarkers for the non-invasive diagnosis of Hepatocellular carcinoma. This research, funded by the Higher Education Commission (HEC) of Pakistan, helped enhance non-invasive diagnostic techniques, contributing to more rapid and accurate cancer diagnosis.
At Trials360, Arslan Ali ensures that clinical trials comply with Good Manufacturing Practices (GMP) and meet regulatory requirements, guaranteeing that clinical research maintains the highest standards of accuracy and integrity. With a strong focus on optimizing protocols and monitoring outcomes, he facilitates the translation of scientific research into effective clinical solutions, playing a key role in advancing healthcare innovation.
Iffat Raheem, a Business Development Representative at Trials 360. She’s a dedicated professional with strong academic background, including a Master’s degree from the University of Agriculture, Faisalabad, and an MPhil in Zoology from Minhaj University, Lahore. She’s also completed a teaching degree from Allama Iqbal Open University, Islamabad, and a Career Preparation Fellowship from Amal Academy.
With a background in teaching and research on animal feeds, Iffat brings a unique perspective to her role. She’s passionate about improving healthcare globally and is committed to contributing her best to Trials 360’s vision.
Muhammad Irfan, a Clinical Research Associate at Trials360, stands as a dedicated professional contributing significantly to the organization’s clinical trials initiatives. He completed his master’s degree in healthcare biotechnology from the prestigious National University of Sciences and Technology (NUST) in Islamabad, Pakistan. His research was focused on the synthesis and biomedical applications of metallic nanoparticles. Muhammad has published a total of 7 papers and a book chapter, showcasing his commitment to advancing scientific knowledge. Leveraging his academic excellence, he transitioned seamlessly into the industry, serving as a Junior Scientist in a US-based company, where he played a vital role in the development of non-invasive diagnostics. In his role at Trials360, Muhammad brings a unique blend of academic prowess and practical experience, ensuring precision and dedication in every research endeavor. As Trials360 continues to redefine possibilities in clinical research, Muhammad stands at the forefront, contributing to the organization’s vision with his commitment to excellence and passion for advancing healthcare solutions globally.
A pharmacist by qualification of 26 years’ experiences mainly in pharmaceutical regulations and compliance. Interested in learning, sharing, and creating stage for promotion of debate and discussion within good science. Received bachelor’s degree independently both in Science (B.Sc.) and Pharmacy (B. Pharm.), Master of Philosophy (M.Phil.) in Neuropharmacology, Doctor of Philosophy (Ph.D.) in Pharmaceutical Chemistry and Post Doc working is in Quality and Regulatory Sciences. Participated in a series of trainings of international regulators on pre-market & post-market reviews and compliance inspections/ investigations from US-FDA, Health Canada, and World Health Organization. Taught Pharmaceutical Regulatory Sciences and conducted training of regulators for different countries. Visited and inspected pharmaceutical & biological manufacturing facilities of developing, emerging, and developed countries across the globe.
